Ozempic can reduce metabolic risks in schizophrenia patients, multicenter study finds

Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with schizophrenia spectrum disorders, according to a study published in JAMA ...
ascopubs.org

ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine ...

Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation Eligible patients ...
TipRanks on MSN

Pfizer’s Protonix pediatric study completion: What investors should watch next

Pfizer Inc ($PFE) announced an update on their ongoing clinical study. Study Overview: Pfizer (PFE) is running a Phase 2 study titled “AN ...

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest prospective, multicenter study to date ...
Pharmabiz

Combination of Castle Biosciences’ DecisionDx-UM and PRAME show predicting outcomes in patients with uveal melanoma: Study

Combination of Castle Biosciences’ DecisionDx-UM and PRAME show predicting outcomes in patients with uveal melanoma: Study: Friendswood, Texas Friday, December 19, 2025, 15:00 H ...
wvgazettemail.com

Clywedog Therapeutics Announces Activation of All Centers and Patient Dosing in Multicenter, International Phase 1b Clinical Study of Balomenib in Type 2 Diabetes

Clywedog Therapeutics, Inc., a clinical-stage biotechnology company advancing novel therapies for metabolic diseases, today announced the activation of all clinical centers and patient ...